|
1
|
Ohgaki H and Kleihues P: Genetic
alterations and signaling pathways in the evolution of gliomas.
Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ng SS, Cheung YT, An XM, Chen YC, Li M, Li
GH, Cheung W, Sze J, Lai L, Peng Y, et al: Cell cycle-related
kinase: A novel candidate oncogene in human glioblastoma. J Natl
Cancer Inst. 99:936–948. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai EC: Micro RNAs are complementary to
3′UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huntzinger E and Izaurralde E: Gene
silencing by microRNAs: Contributions of translational repression
and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fu LL, Wen X, Bao JK and Liu B:
MicroRNA-modulated autophagic signaling networks in cancer. Int J
Biochem Cell Biol. 44:733–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Jaarsveld MT, Helleman J, Berns EM and
Wiemer EA: MicroRNAs in ovarian cancer biology and therapy
resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janga SC and Vallabhaneni S: MicroRNAs as
post-transcriptional machines and their interplay with cellular
networks. Adv Exp Med Biol. 722:59–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paulin R, Courboulin A, Barrier M and
Bonnet S: From oncoproteins/tumor suppressors to microRNAs, the
newest therapeutic targets for pulmonary arterial hypertension. J
Mol Med (Berl). 89:1089–1101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gabriely G, Yi M, Narayan RS, Niers JM,
Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM, et
al: Human glioma growth is controlled by microRNA-10b. Cancer Res.
71:3563–3572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han
L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, et al: miR-221 and
miR-222 target PUMA to induce cell survival in glioblastoma. Mol
Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang V and Wu W: MicroRNA-based
therapeutics for cancer. BioDrugs. 23:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chase A and Cross NC: Aberrations of EZH2
in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bracken AP, Dietrich N, Pasini D, Hansen
KH and Helin K: Genome-wide mapping of polycomb target genes
unravels their roles in cell fate transitions. Genes Dev.
20:1123–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iliopoulos D, Lindahl-Allen M, Polytarchou
C, Hirsch HA, Tsichlis PN and Struhl K: Loss of miR-200 inhibition
of Suz12 leads to polycomb-mediated repression required for the
formation and maintenance of cancer stem cells. Mol Cell.
39:761–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Villa R, Pasini D, Gutierrez A, Morey L,
Occhionorelli M, Viré E, Nomdedeu JF, Jenuwein T, Pelicci PG,
Minucci S, et al: Role of the polycomb repressive complex 2 in
acute promyelocytic leukemia. Cancer Cell. 11:513–525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herranz N, Pasini D, Díaz VM, Francí C,
Gutierrez A, Dave N, Escrivà M, Hernandez-Muñoz I, Di Croce L,
Helin K, et al: Polycomb complex 2 is required for E-cadherin
repression by the Snail1 transcription factor. Mol Cell Biol.
28:4772–4781. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder
cancer metastasis by associating with suz12. Clin Cancer Res.
20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui Y, Chen J, He Z and Xiao Y: SUZ12
depletion suppresses the proliferation of gastric cancer cells.
Cell Physiol Biochem. 31:778–784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martin-Perez D, Sanchez E, Maestre L,
Suela J, Vargiu P, Di Lisio L, Martínez N, Alves J, Piris MA and
Sánchez-Beato M: Deregulated expression of the polycomb-group
protein SUZ12 target genes characterizes mantle cell lymphoma. Am J
Pathol. 177:930–942. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang J, Zhang J, Zhang J, Qiu W, Xu S, Yu
Q, Liu C, Wang Y, Lu A, Zhang J and Lu X: MicroRNA-625 inhibits the
proliferation and increases the chemosensitivity of glioma by
directly targeting AKT2. Am J Cancer Res. 7:1835–1849.
2017.PubMed/NCBI
|
|
31
|
Henriksen JR, Haug BH, Buechner J, Tømte
E, Løkke C, Flaegstad T and Einvik C: Conditional expression of
retrovirally delivered anti-MYCN shRNA as an in vitro model system
to study neuronal differentiation in MYCN-amplified neuroblastoma.
BMC Dev Biol. 11:12011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang G, Mao W and Zheng S: MicroRNA-183
regulates Ezrin expression in lung cancer cells. FEBS Lett.
582:3663–3668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang YY, Sun G, Luo H, Wang XF, Lan FM,
Yue X, Fu LS, Pu PY, Kang CS, Liu N and You YP: miR-21 modulates
hTERT through a STAT3-dependent manner on glioblastoma cell growth.
CNS Neurosci Ther. 18:722–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Møller HG, Rasmussen AP, Andersen HH,
Johnsen KB, Henriksen M and Duroux M: A systematic review of
microRNA in glioblastoma multiforme: Micro-modulators in the
mesenchymal mode of migration and invasion. Mol Neurobiol.
47:131–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang Q, Gumireddy K, Schrier M, le Sage
C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al:
The microRNAs miR-373 and miR-520c promote tumour invasion and
metastasis. Nat Cell Biol. 10:202–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bou Kheir T, Futoma-Kazmierczak E,
Jacobsen A, Krogh A, Bardram L, Hother C, Grønbæk K, Federspiel B,
Lund AH and Friis-Hansen L: miR-449 inhibits cell proliferation and
is down-regulated in gastric cancer. Mol Cancer. 10:292011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin
ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M and Zhang R:
SUZ12 promotes human epithelial ovarian cancer by suppressing
apoptosis via silencing HRK. Mol Cancer Res. 10:1462–1472. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC,
Cui BB and Yang YM: Expression and clinicopathological significance
of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin
Oncol. 141:661–669. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Peng F, Jiang J, Yu Y, Tian R, Guo X, Li
X, Shen M, Xu M, Zhu F, Shi C, et al: Direct targeting of
SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma
tumourigenesis and metastasis. Br J Cancer. 109:3092–3104. 2013.
View Article : Google Scholar : PubMed/NCBI
|
